EVFM Evofem Biosciences Inc.

6.03
-0.18  -3%
Previous Close 6.21
Open 6.19
Price To Book 11.82
Market Cap 282,269,142
Shares 46,810,803
Volume 2,816
Short Ratio
Av. Daily Volume 77,685
Stock charts supplied by TradingView

NewsSee all news

  1. PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®

    INCLINE VILLAGE, Nev., Dec. 3, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ:EVFM) on its recent

  2. Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women

    SAN DIEGO, Dec. 2, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical stage biopharmaceutical company, today announced positive top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating

  3. Evofem Biosciences Resubmits New Drug Application to U.S. FDA for Amphora® for the Prevention of Pregnancy

    SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and

  4. Evofem Biosciences' CEO Saundra Pelletier Awarded 2019 Business Woman Of The Year

    SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier was named a 2019 Business Woman of the Year by the San Diego Business

  5. Evofem Biosciences to Participate in Upcoming Investor Conferences

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present at two upcoming

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data met primary endpoint - December 2, 2019.
Amphora - AMPREVENCE
Prevention of urogenital Chlamydia trachomatis infection in women
NDA resubmission announced November 26, 2019.
Amphora - AMPOWER
contraceptive vaginal gel

Latest News

  1. PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®

    INCLINE VILLAGE, Nev., Dec. 3, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ:EVFM) on its recent

  2. Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women

    SAN DIEGO, Dec. 2, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical stage biopharmaceutical company, today announced positive top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating

  3. Evofem Biosciences Resubmits New Drug Application to U.S. FDA for Amphora® for the Prevention of Pregnancy

    SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and

  4. Evofem Biosciences' CEO Saundra Pelletier Awarded 2019 Business Woman Of The Year

    SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier was named a 2019 Business Woman of the Year by the San Diego Business

  5. Evofem Biosciences to Participate in Upcoming Investor Conferences

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present at two upcoming

  6. Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM) a clinical-stage biopharmaceutical company, today reported financial results for the three- and nine-month periods ended September 30, 2019.

  7. Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, will present and host investor meetings at the upcoming 2019 Cantor Global Healthcare

  8. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  9. Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) ("Evofem" or the "Company") today announced the last patient has completed her last visit in AMPREVENCE, the Phase 2b

  10. Evofem Biosciences to Present at Upcoming Healthcare Conferences

    SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, is set to present at two healthcare equity conferences in early September.